NeuroVive Pharmaceutical AB, the mitochondrial medicine company, has announced the appointment of Daniel Schale as director of communications. Daniel will report to CFO Catharina Johansson.
Schale will be responsible for the company's communications, media relations and public affairs. He has ten years of experience in PR and communications, in recent years with special focus on pharmaceuticals, biotech and life science. He holds an M.Sc. in Economics from Lund University and joins NeuroVive from a role as senior corporate communications and public affairs advisor with the Swedish PR-firm Aspekta. Having been responsible for clients in the pharmaceutical and life science industries, Schalel has worked with lobbying, advocacy and disease awareness, as well as market access communications.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury and one project in clinical phase for genetic mitochondrial diseases.